Update date: Jul 08, 2026 | 150 Pages | Report ID: HO-003256
Liquid Embolic Agent Market
DMA IntelligenceLiquid Embolic Agent Emerging Trends & Growth Outlook 2033
Segments: Product Type (Ethylene Vinyl Alcohol Copolymer (EVOH), Cyanoacrylates, Others), Application (Arteriovenous Malformations (AVM), Hypervascular Tumors, Peripheral Vasculature Hemorrhage, Others), End Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Others), By Region, And Segment Forecasts
$850.0M
Market Size, 2025
$930.8M
Market Estimate, 2026
$1756.8M
Market Forecast, 2033
9.5%
CAGR, 2026–2033
Liquid Embolic Agent Market Size, Share & Key Insights
The Liquid Embolic Agent Market size was valued at USD 850.00 Million in 2025, and the market is projected to grow from USD 930.75 Million in 2026 to USD 1756.84 Million by 2033, growing at a CAGR of 9.5% during the forecast period 2026–2033. The market saw distributed global demand in 2025.
Study Overview
 Study Period | 2021 - 2033 |
 Base Year | 2025 |
 Estimated Year | 2026 |
 Forecast Period | 2026-2033 |
 Historical Range | 2021-2025 |
| Units | USD Million |
 Coverage | Global | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
 Deliverables | PDF + Excel Data Pack |
Major Market Players
Key Insights
- The global Liquid Embolic Agent market is projected to reach USD 1,757.29 Million by 2033, growing from USD 850.00 Million in 2025 at a robust CAGR of 9.50% during the forecast period, driven by increasing adoption of minimally invasive procedures.
- North America currently dominates the market with the largest share in 2025, primarily due to advanced healthcare infrastructure and high awareness, while Asia Pacific is anticipated to emerge as the fastest-growing market, fueled by improving healthcare access and rising medical tourism.
- The Onyx product type segment held the largest market share in 2025, reflecting its established clinical utility and widespread preference among neurovascular specialists for treating complex vascular malformations.
Market Definition and Strategic Context
The Liquid Embolic Agent Market refers to the specialized segment within medical devices focused on the development, manufacturing, and distribution of injectable materials used to occlude or block blood vessels, primarily in the treatment of vascular malformations, aneurysms, and hypervascular tumors. These agents are crucial in minimally invasive neurovascular and peripheral interventions, offering an alternative to traditional surgical methods. The market is driven by technological advancements in catheter-based delivery systems, increasing prevalence of neurological disorders, and a growing demand for less invasive treatment options globally. Liquid embolic agents, such as Onyx, Squid, PHIL, and Trufill, are designed to solidify upon contact with blood, creating a permanent occlusion. Their application requires specialized skills and equipment, contributing to a niche yet rapidly expanding sector within interventional radiology and neurosurgery. The Liquid Embolic Agent market size is significantly influenced by regulatory approvals, clinical evidence supporting efficacy and safety, and the adoption rates in both developed and emerging healthcare economies. The ongoing innovation in agent formulations, aimed at improving deliverability, visibility under fluoroscopy, and long-term stability, is a key determinant of the industry's expansion. Furthermore, the market's growth outlook is bolstered by an aging global population, which is more susceptible to conditions requiring neurovascular interventions. The market also benefits from increased awareness and diagnostic capabilities for these conditions. The market forecast indicates sustained growth, reflecting the continuous integration of these advanced materials into standard clinical practice. Industry expansion is also fueled by strategic collaborations between device manufacturers and healthcare providers to enhance training and accessibility. In 2025, the global Liquid Embolic Agent market was valued at approximately USD 850.00 Million, underscoring its significant role in modern medical interventions.
| Report Attribute | Details |
|---|---|
| Market size value in 2025 | USD 850.00 Million |
| Revenue forecast in 2033 | USD 1,756.84 Million |
| Growth rate | CAGR of 9.5% from 2025 to 2033 |
| Actual data | 2021 - 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD Million and CAGR from 2025 to 2033 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Product Type, Application, End Use |
| Regional scope | Middle East |
| Country scope | Saudi Arabia; UAE; Kuwait; Oman; Qatar |
| Key companies profiled | Medtronic; B. Braun SE; Terumo; Gem srl; Meril |
| Customization scope | Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Growth Catalysts & Market Constraints
The Liquid Embolic Agent market is characterized by a complex interplay of factors driving its expansion and those posing significant hurdles to broader adoption. Understanding these dynamics is crucial for stakeholders to navigate the evolving landscape effectively. The market's growth forecast is intrinsically linked to advancements in neurovascular intervention techniques and the increasing global burden of vascular diseases. However, the specialized nature of these procedures and the high cost associated with both the agents and the delivery systems present notable constraints. Industry expansion is further influenced by the pace of regulatory approvals and the robust clinical data required to demonstrate long-term safety and efficacy. Strategic investments in research and development, coupled with efforts to enhance physician training, are pivotal for sustaining the Liquid Embolic Agent market's upward trajectory. The global Liquid Embolic Agent market size continues to expand as healthcare systems increasingly prioritize minimally invasive treatments, yet challenges related to market access and competition from alternative therapies remain prominent.
Growth Drivers
- The escalating global prevalence of neurovascular disorders such as aneurysms, arteriovenous malformations (AVMs), and hypervascular tumors significantly drives the demand for liquid embolic agents. As diagnostic capabilities improve and an aging population becomes more susceptible to these conditions, the need for effective, minimally invasive treatment options like liquid embolic agents intensifies, fueling market expansion and adoption across healthcare systems worldwide.
- Technological advancements in catheter-based delivery systems and the development of new-generation liquid embolic agents are propelling market growth. Innovations enhancing navigability, precision, and safety during complex neurovascular interventions, alongside agents with improved material properties and fluoroscopic visibility, encourage broader clinical adoption and expand the scope of treatable conditions, thereby increasing market size and revenue.
Restraints
- The high cost associated with liquid embolic agents and the specialized interventional procedures required for their application acts as a significant restraint, particularly in cost-sensitive healthcare markets. This financial burden can limit patient access, restrict adoption in developing regions, and impose budget pressures on hospitals, thereby hindering the overall market penetration and growth potential of these advanced medical devices.
- The stringent regulatory approval processes and the need for extensive clinical evidence to demonstrate long-term safety and efficacy of new liquid embolic agents pose substantial hurdles. Delays in regulatory clearances and the high investment required for clinical trials can impede product innovation and market entry, slowing the overall pace of industry expansion and limiting competitive diversification.
Opportunities
- Emerging economies, particularly in Asia Pacific and Latin America, present significant growth opportunities due to their rapidly developing healthcare infrastructures, increasing healthcare expenditure, and a large underserved patient population. Strategic market entry and localized distribution networks in these regions can unlock substantial revenue potential, leveraging growing awareness and improving access to advanced neurovascular treatments.
- Expansion of indications for liquid embolic agents beyond neurovascular applications into areas such as peripheral vascular interventions and tumor embolization offers a lucrative opportunity. Clinical research exploring new therapeutic uses and the development of agents tailored for specific non-neurovascular conditions could significantly broaden the market's addressable patient base and diversify revenue streams for manufacturers.
Challenges
- The technical complexity and steep learning curve associated with the precise delivery of liquid embolic agents pose a significant challenge. This requires extensive training and specialized expertise for interventional radiologists and neurosurgeons, limiting the number of qualified practitioners and potentially restricting the wider adoption of these procedures, thereby impacting market volume.
- Competition from alternative treatment modalities, including surgical clipping, coiling, and radiation therapy, presents a continuous challenge for the liquid embolic agent market. While minimally invasive, liquid embolization must consistently demonstrate superior or equivalent outcomes, cost-effectiveness, and fewer complications to maintain its competitive edge and drive sustained market share growth.
Market Level Breakdown
The Liquid Embolic Agent market is segmented by Product Type into Onyx, Squid, PHIL, and Trufill, reflecting the diverse range of materials available to clinicians. Onyx, a non-adhesive liquid embolic system, has historically held a significant share due to its controlled delivery and established clinical profile in various neurovascular applications. Squid and PHIL agents, representing newer generations, offer unique properties such as improved visibility and reduced artifacts, fostering their increasing adoption. Trufill, another key product, provides specialized solutions for specific clinical scenarios. This segmentation highlights the ongoing innovation in material science and delivery systems aimed at enhancing procedural safety and efficacy, which collectively contribute to the overall Liquid Embolic Agent market size.
Based on Application, the Liquid Embolic Agent market is categorized into AVMs (Arteriovenous Malformations), Aneurysms, Tumors, and Other applications. The AVMs segment typically commands a substantial share, as liquid embolic agents are a primary treatment modality for these complex vascular lesions, offering effective and minimally invasive occlusion. Aneurysms also represent a critical application, particularly for complex or giant aneurysms where coiling alone might be insufficient. The use in treating hypervascular Tumors is expanding, providing a pre-operative or palliative embolization option. The 'Other' category includes various peripheral and visceral applications, indicating the versatility and expanding utility of these agents. This application-based segmentation underscores the specific clinical needs driving the demand and market forecast for liquid embolic agents.
The End Use segmentation of the Liquid Embolic Agent market includes Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Research Institutes. Hospitals, particularly those with advanced neurovascular and interventional radiology departments, represent the largest end-use segment due to their capacity for complex procedures, emergency care, and comprehensive patient management. ASCs are gaining traction as they offer cost-effective settings for select procedures, driving market growth in outpatient settings. Specialty Clinics focus on specific vascular conditions, contributing to targeted demand, while Research Institutes play a crucial role in developing new agents and expanding indications. This granular segmentation provides insights into the diverse healthcare delivery channels influencing the Liquid Embolic Agent market's industry expansion and adoption patterns.
Liquid Embolic Agent Segmentation Breakdown
- Product Type
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates
- Others
- Application
- Arteriovenous Malformations (AVM)
- Hypervascular Tumors
- Peripheral Vasculature Hemorrhage
- Others
- End Use
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Others
Geographic Performance & Regional Trends
Regionally, the Liquid Embolic Agent market exhibits distinct growth patterns, with North America leading in terms of market share in 2025, primarily due to its advanced healthcare infrastructure, high prevalence of neurological disorders, and early adoption of innovative medical technologies. The robust reimbursement policies and significant R&D investments in countries like the United States and Canada have further cemented its dominance. Conversely, Asia Pacific is projected to be the fastest-growing market for Liquid Embolic Agents, driven by improving healthcare access, rising medical tourism, and increasing awareness of minimally invasive procedures in populous countries such as China and India. The region's expanding patient pool and growing healthcare expenditure are key factors contributing to this accelerated Liquid Embolic Agent market growth.
Regional Growth Drivers
- North America: The region's robust healthcare infrastructure, high per capita healthcare spending, and favorable reimbursement policies are significant drivers. Early adoption of advanced medical technologies and the presence of leading manufacturers further contribute to market leadership. The high prevalence of neurovascular conditions, coupled with a strong emphasis on minimally invasive treatments in countries like the United States, ensures sustained demand and innovation in liquid embolic agents.
- Europe: Increasing awareness regarding neurovascular diseases and the rising demand for less invasive surgical procedures are propelling market growth. Supportive government initiatives for healthcare modernization and high-quality medical research in countries such as Germany, the United Kingdom, and France enhance the adoption of liquid embolic agents. The presence of a well-established medical device industry also fosters innovation and market expansion.
- Asia Pacific: This region is experiencing rapid market growth due to improving healthcare facilities, increasing disposable incomes, and a large patient base. Government investments in healthcare infrastructure and the growing trend of medical tourism, particularly in countries like China, Japan, and India, are driving the adoption of advanced neurovascular treatments, positioning Asia Pacific as a high-potential market for liquid embolic agents.
- Latin America: Modernization of healthcare systems and increasing patient access to specialized medical treatments are key growth drivers. Growing awareness about neurovascular conditions and the availability of advanced diagnostic tools contribute to the expanding application of liquid embolic agents. Countries such as Brazil and Mexico are witnessing rising demand for minimally invasive procedures, fueling market development in the region.
- Middle East & Africa: Enhanced healthcare spending, a focus on upgrading medical facilities, and increasing prevalence of chronic diseases are stimulating market growth. Efforts to improve access to advanced medical technologies and specialized treatments, particularly in countries like Saudi Arabia and South Africa, are creating new opportunities for liquid embolic agents, albeit from a smaller base, contributing to regional healthcare advancements.
Looking ahead, the regional forecast indicates a divergence in market trajectories. Mature markets like North America and Europe will likely experience steady, incremental growth, driven by continued innovation and refinements in existing procedures. In contrast, emerging regions such as Asia Pacific and Latin America are poised for accelerated expansion, fueled by increasing healthcare penetration and a growing demand for advanced treatments. Suppliers must strategically focus on market access, localized product offerings, and physician training initiatives to capitalize on the high-growth potential in these developing economies, while maintaining their leadership in established markets through product differentiation and clinical excellence.
Competitive Insights & Leading Companies
The Liquid Embolic Agent market competitive landscape is best described as moderately consolidated, characterized by the presence of a few dominant global players alongside a scattering of regional and specialized companies. Leading entities such as Medtronic, B. Braun SE, and Terumo command significant market shares, leveraging their extensive product portfolios, established distribution networks, and strong brand recognition. These global players typically compete on the basis of technological innovation, clinical evidence, and regulatory approvals, which are critical for market entry and sustained growth in this specialized medical device sector. Regional players often focus on niche segments or specific geographic markets, sometimes offering cost-effective alternatives or localized support. Key competitive levers include pricing strategies, which must balance innovation costs with market accessibility, robust distribution channels to reach specialized medical centers, and continuous product innovation to enhance efficacy, safety, and ease of use. Regulatory approvals and certifications are paramount, as the market is highly regulated, requiring rigorous clinical trials and adherence to international standards. Companies that can demonstrate superior outcomes and provide comprehensive training for clinicians gain a significant competitive advantage. The market also sees competition in terms of offering integrated solutions that combine embolic agents with advanced delivery systems.
Strategies employed by leading companies in the Liquid Embolic Agent market frequently involve a mix of organic and inorganic growth initiatives. Mergers and acquisitions are common, allowing larger players to expand their product offerings, acquire innovative technologies, or strengthen their market presence in key regions. Partnerships with academic institutions and research organizations are crucial for advancing R&D efforts and bringing next-generation agents to market. Product launches are carefully orchestrated, often following extensive clinical trials and regulatory clearances, with a focus on highlighting unique selling propositions such as improved flow characteristics, better fluoroscopic visibility, or enhanced biocompatibility. Geographic expansion, particularly into underserved emerging markets, represents a significant growth strategy, often accompanied by localized marketing and distribution efforts. Differentiation is achieved through various means, including proprietary material formulations that offer distinct clinical advantages, superior service models that include comprehensive physician training and technical support, and strong channel strength through direct sales forces or strategic distributor alliances. Customization options, though limited in medical devices, can include varying product sizes or delivery system configurations. However, the market faces challenges such as intense margin pressure due to increasing healthcare cost containment efforts and the high fixed costs associated with R&D and regulatory compliance. Ensuring a resilient supply chain for these specialized agents is also critical to avoid disruptions and maintain market share in a highly sensitive clinical environment.
Liquid Embolic Agent Key Companies
- Medtronic
- B. Braun SE
- Terumo
- Gem srl
- Meril
Liquid Embolic Agent Market Ecosystem
Ecosystem Participants
- Manufacturers — These entities are at the core of the ecosystem, responsible for the research, development, production, and commercialization of liquid embolic agents and their associated delivery systems. They invest heavily in R&D to innovate new formulations and improve existing products, ensuring compliance with stringent regulatory standards and conducting extensive clinical trials to validate safety and efficacy. Their role extends to global distribution and providing technical support to healthcare providers.
- Their operational responsibilities include managing complex supply chains, securing intellectual property, and navigating diverse regulatory landscapes across different countries. They also play a crucial role in post-market surveillance and continuous product improvement based on clinical feedback and adverse event reporting.
- Healthcare Providers — This group encompasses hospitals, ambulatory surgical centers, and specialty clinics where interventional procedures using liquid embolic agents are performed. Neurosurgeons, interventional radiologists, and other specialists are key decision-makers and end-users. Their role involves patient diagnosis, treatment planning, performing complex embolization procedures, and managing post-procedural patient care and follow-up.
- Providers are responsible for ensuring proper training of their medical staff, maintaining state-of-the-art infrastructure, and adhering to strict clinical protocols and patient safety guidelines. They also influence product adoption through their clinical experience and feedback to manufacturers, impacting future product development.
- Regulatory Bodies — Agencies such as the FDA (United States), EMA (Europe), and PMDA (Japan) are critical for ensuring the safety, efficacy, and quality of liquid embolic agents. They establish guidelines for product development, clinical trials, manufacturing practices, and market authorization. Their oversight is crucial for maintaining public trust and safeguarding patient health.
- These bodies conduct rigorous assessments of new devices, monitor post-market performance, and enforce compliance, which can significantly impact market entry timelines and product design for manufacturers. Their decisions directly influence product availability and market access.
- Distributors and Supply Chain Providers — These participants facilitate the movement of liquid embolic agents from manufacturers to healthcare providers globally. They manage logistics, warehousing, inventory, and often provide sales and marketing support. Their efficiency is vital for ensuring timely delivery of these critical medical supplies, especially for emergency procedures.
- They often specialize in medical devices, requiring cold chain management and adherence to specific handling protocols. Their role is to optimize the supply chain, manage regional market access, and ensure that products are available where and when needed, bridging the gap between producers and end-users.
- Research and Academic Institutions — These organizations contribute significantly to the ecosystem through fundamental research, preclinical studies, and clinical trials that advance the understanding and application of liquid embolic agents. They often collaborate with manufacturers to evaluate new technologies and develop innovative treatment protocols, fostering scientific progress and evidence generation.
- Their contributions include publishing clinical data, developing new surgical techniques, and training the next generation of interventional specialists. They are instrumental in translating scientific discoveries into practical clinical applications, shaping the future direction and adoption of embolic therapies.
- Patient Advocacy Groups — These non-profit organizations represent the interests of patients suffering from conditions treated by liquid embolic agents, such as AVMs or aneurysms. They play a vital role in raising awareness, providing patient support and education, and advocating for improved access to diagnosis, treatment, and funding for research.
- By amplifying patient voices, these groups can influence healthcare policies, funding decisions, and the research agendas of manufacturers and academic institutions, ensuring that patient needs and perspectives are integrated into the development and delivery of care.
Report Coverage & Key Deliverables
The report delivers a comprehensive analysis of the Liquid Embolic Agent, combining quantitative data with qualitative insights. This exhaustive study provides a strategic overview of the market, offering critical intelligence for stakeholders, investors, and industry participants. It meticulously breaks down the market by key segments, including product type, application, and end-use, across various geographical regions, ensuring a granular understanding of market dynamics. Decision-makers can leverage this report to identify emerging trends, assess competitive landscapes, and formulate robust business strategies. The report's scope encompasses historical market performance, current market size, and future growth projections, presenting a holistic view of the industry's trajectory. By integrating detailed data with expert analysis, the report aims to equip readers with actionable insights necessary for informed decision-making, enabling them to capitalize on growth opportunities and mitigate potential risks within the dynamic Liquid Embolic Agent market. Its clarity and depth make it an indispensable resource for anyone looking to understand or enter this specialized medical device sector.
Report Coverage
- Market Size Estimates (historical and forecast)
- Our report provides meticulously calculated market size estimates, spanning historical data from 2021 to 2025 and comprehensive forecasts extending to 2033. These estimates are derived using a rigorous methodology that combines primary research with secondary data analysis, ensuring accuracy and reliability for strategic planning and investment decisions.
- Detailed Segmentation And Revenue Analysis
- The study offers an in-depth segmentation of the Liquid Embolic Agent market by product type, application, and end-use, coupled with detailed revenue analysis for each segment. This granular breakdown enables stakeholders to identify high-growth areas, understand market concentration, and tailor their product development and marketing strategies effectively.
- Regional And Country-Level Insights
- We deliver comprehensive regional and country-level insights, highlighting market performance across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. This section analyzes specific growth drivers, regulatory landscapes, and competitive dynamics unique to each geography, aiding in targeted market entry and expansion strategies.
- Competitive Benchmarking Of Key Players
- The report includes an exhaustive competitive benchmarking of key players, profiling leading companies like Medtronic, B. Braun SE, and Terumo. This analysis covers their strategic initiatives, product portfolios, market positioning, and recent developments, providing a clear understanding of the competitive landscape and potential partnership opportunities.
- Customization Options Based on Specific Requirements
- Understanding that each client has unique needs, we offer extensive customization options. This allows clients to tailor the report's scope, focus on specific market segments, regions, or competitive aspects, and receive data in their preferred format, ensuring maximum relevance and value for their strategic objectives.
Recent Industry Insights
The Liquid Embolic Agent industry has witnessed several significant developments over the past 12-18 months, reflecting a dynamic landscape shaped by technological advancements and strategic collaborations. Key players have been focusing on enhancing product portfolios through R&D and securing regulatory approvals for next-generation agents that offer improved deliverability and clinical outcomes. Partnerships between device manufacturers and healthcare institutions have become more prevalent, aiming to expand clinical training and facilitate broader adoption of these specialized therapies. Shifts in treatment paradigms towards minimally invasive procedures continue to drive demand, with an increasing emphasis on patient safety and long-term efficacy. Furthermore, there's been a noticeable trend of companies investing in emerging markets, recognizing the untapped potential and growing healthcare infrastructure in these regions. These Liquid Embolic Agent industry trends underscore a commitment to innovation and market expansion, adapting to evolving clinical needs and global healthcare demands.
Key Market Developments
- October 2024: Medtronic announced the successful completion of a pivotal clinical trial for its new liquid embolic agent, demonstrating superior safety and efficacy in treating complex brain AVMs in the United States.
- August 2024: Terumo launched an advanced microcatheter specifically designed for enhanced delivery of liquid embolic agents, improving precision and control during neurovascular interventions across Europe.
- June 2024: B. Braun SE entered into a strategic partnership with a leading hospital network in India to establish specialized training centers for neurovascular embolization procedures, aiming to boost product adoption in the region.
- March 2024: Gem srl received CE Mark approval for its next-generation liquid embolic system, paving the way for its commercialization across the European Union and expanding its market reach.
- January 2024: Meril expanded its manufacturing capacity for interventional neurovascular devices, including liquid embolic agents, in Asia Pacific to meet the rising global demand for minimally invasive treatments.
Analyst Opinion
The Liquid Embolic Agent market presents a highly attractive investment proposition, underpinned by the increasing prevalence of neurovascular disorders and the growing preference for minimally invasive surgical techniques. The market's competitive intensity is moderately consolidated, with established global players holding significant sway, but also allowing room for specialized innovators. The demand for these agents is consistently outstripping supply in certain developing regions, indicating substantial untapped potential. Technological advancements in both the agents themselves and their delivery systems are continually expanding the addressable patient population and improving procedural outcomes, reinforcing market attractiveness. The market outlook remains positive, driven by ongoing clinical research, expanding indications beyond neurovascular applications, and the demographic tailwind of an aging global population. While regulatory hurdles and the need for specialized physician training present barriers to entry, the long-term benefits for patient care and the economic advantages of reduced hospital stays continue to fuel sustained growth.
Looking at the long-term outlook, the Liquid Embolic Agent market is poised for robust expansion, with innovation remaining at the forefront. The innovation landscape is dynamic, focusing on developing agents with enhanced radiopacity, improved flow characteristics, and reduced inflammatory responses, alongside more intuitive and precise delivery systems. Key risk factors include the high cost of R&D, the potential for adverse events, and the prolonged regulatory approval cycles which can delay market entry for novel products. Additionally, competition from alternative therapies, though less invasive, demands continuous demonstration of superior efficacy and safety profiles. Strategic implications for market players involve prioritizing investments in cutting-edge research, fostering collaborative partnerships with leading clinical centers, and developing comprehensive training programs for healthcare professionals. Companies that can effectively navigate the regulatory complexities and demonstrate clear clinical advantages will be well-positioned to capture significant market share and sustain long-term growth in this specialized and high-value segment of the medical device industry.